Tags : Exact Sciences

Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B

Shots: Exact Sciences to acquire Thrive in all cash & stock transaction for ~2.15B out of which $1.7B would be payable at closing, consisting of 65% in Exact Sciences common stock and 35% in cash along with ~$450M as milestones related to the development and commercialization of a blood-based, multi-cancer screening test. The transaction is […]Read More

Exact Sciences and Pfizer Announce Extension and Amendment of their

Shots: Pfizer will continue to provide sales and marketing support and health system support for Cologuard through the end of 2022 and 2021, respectively. Exact Sciences will compensate Pfizer based on the amount of services provided, along with additional fixed and performance-related fees set forth in the agreement Cologuard was approved by US FDA in […]Read More

Top 20 Diagnostics Companies Based on 2019 Revenue

Diagnostics has emerged as one of the largest and fastest-growing segments with evolving diseases. The segment has played a vital role in diagnosing growing and ageing global population with increasing health expenditure and more prevalent lifestyle ailments including obesity, cancer, and cardiovascular diseases. Our team at PharmaShots has compiled a list of top 20 diagnostics […]Read More

PharmaShots Weekly Snapshot (October 14-18, 2019)

1. Johnson & Johnson Initiates Voluntarily Recall of a Single Lot of its Baby Powder in the US Published: Oct 18, 2019 | Tags: JnJ, Initiates, Voluntarily, Recall, Baby Powder, US 2. AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis Published: Oct 18, 2019 | Tags: AbbVie, Rinvoq, Upadacitinib, Receives, […]Read More

Exact Sciences and Mayo Clinic Initiate Voyage Study Evaluating the

Shots: Exact & Mayo has initiated the Voyage study to generate evidence of the real-world impact of Cologuard on colorectal cancer screening, incidence, and mortality rates. The Voyage study will provide additional, real-world evidence demonstrating the clinical impact of Cologuard & position it as SoC in colorectal cancer screening The Voyage study is a prospective, […]Read More

Exact Sciences to Merge with Genomic Health Forming a New

Shots: Exact Sciences enter into a merger agreement with Genomic in cash & stock transaction for $72/share making the total deal value $2.8B. Genomic to receive $27.50 in cash & $44.50 in shares of Exact Sciences stock for each owned share based on the closing price value as of Jul 26, 2019. The transaction is […]Read More